ArticleFolia microbiologica2025
Evaluation of the interaction and synergy potential of bedaquiline and clarithromycin in combination with efflux pump inhibitors in clinical isolates of Mycobacterium abscessus complex.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Nontuberculous mycobacteria (NTM) cause difficult-to-treat pulmonary infections due to their high antimicrobial resistance. Among them, the Mycobacterium abscessus complex (MABC) is a major pathogen characterized by prolonged treatment courses and low success rates. This study investigated the combination effects of the antimicrobials bedaquiline (BDQ) and clarithromycin (CLA) with the efflux pump inhibitors (EPIs) verapamil (VP) and berberine (BER) in clinical MABC isolates. Nineteen MABC strains isolated from respiratory samples were analyzed using the checkerboard method, and fractional inhibitory concentration index (FICI) values were calculated to determine synergistic, indifferent, or antagonistic interactions. Subspecies identification and genotypic resistance profiles were assessed using the GenoType NTM-DR assay. Of the isolates, 84.2% were identified as M. abscessus subsp. abscessus, 10.5% as M. abscessus subsp. massiliense, and 5.26% as M. abscessus subsp. bolletii. While no rrl (acquired macrolide resistance) or rrs (aminoglycoside resistance) mutations were detected, a functional erm41 (inducible macrolide resistance) gene was found in 73.6% of isolates. Synergistic effects were observed at rates of 84.2% for BDQ/VP, 57.9% for CLA/VP, 5.26% for BDQ/BER, and 31.5% for CLA/BER, with no antagonism identified. The BDQ/VP combination showed significantly greater synergy than BDQ/BER (p < 0.0005) and was superior to CLA/VP (p < 0.0005). Combinations with VP demonstrated significantly lower FICI values (p < 0.0005). Median fold increases in antimicrobial activity were four-fold with VP and two-fold with BER. In conclusion, the BDQ/VP combination emerged as the most effective regimen. These results highlight the synergistic potential of EPI-antimicrobial combinations and may inform the development of new therapeutic strategies for NTM infections.
Indexed as
Identifiers
41075152What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.